TickerSpark Feed

ABT coverage

Every article, report, and earnings note where ABT appears.

Davion Healthcare Prices Nasdaq Direct Listing on Home Testing Push

Davion Healthcare Plc is set to list on Nasdaq on 2026-10-22, with a price range not disclosed and a market cap of $252,750,000. The company is coming public as a direct listing, so there is no traditional underwritten IPO bookbuild or IPO proceeds. The bull case is a pre-revenue medtech story with multiple registered products and a consumer OTC model. The bear case is that the stock starts trading without the cushion of an IPO raise, while cash remains extremely thin and execution risk is high.

Oct 21, 2026·6 MIN

IPO NASDAQ

Research ReportABT

Abbott Laboratories (ABT): Libre and Devices Drive Growth

Abbott Laboratories earns a Buy as medical devices and FreeStyle Libre power growth, while margin improvement and raised guidance support the case. Valuation is still premium, so the stock looks attractive but not cheap.

Oct 15, 2026·19 MIN

Healthcare Medical Devices Healthcare

IPOMMEDV

MiniMed Group IPO: The Bull and Bear Case for a Diabetes Carve-Out

MiniMed Group, Inc. Common Stock When Issued is expected to list on NASDAQ on 2026-10-01 under the symbol MMEDV. The price range has not been disclosed yet. The bull case is a global diabetes-tech platform with $3.102 billion in fiscal 2026 sales; the bear case is execution risk, heavy competition, and a float dominated by Medtronic.

Sep 30, 2026·6 MIN

IPO NASDAQ

IPOEMI

Encore Medical IPO: The Bull and Bear Case

Encore Medical Inc. is expected to list on the NYSE on 2026-10-01, but the price range has not been disclosed yet. The setup is straightforward: a structural heart device company with real revenue growth, but also ongoing losses and a hard regulatory path in the U.S.

Sep 29, 2026·5 MIN

IPO NYSE

SPAC

What to Watch as DRC Medicine's SPAC Merger Heads to Close

DRC Medicine is a Tokyo-based healthcare and biotech company going public via a merger with Ribbon Acquisition Corp. (NASDAQ: RIBB). The setup offers a development-stage story with real upside if its mask, diagnostics, and certification pipeline advances, but shareholders should watch redemption risk and dilution closely.

Sep 4, 2026·6 MIN

SPAC Merger De-SPAC

IPOHLTH

What to Watch as Cue Health Prices Its Nasdaq IPO

Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.

Jul 21, 2026·5 MIN

IPO NASDAQ

Trending StockABT

Abbott Laboratories (ABT) climbs 12.5% on Q2 beat

Abbott Laboratories (ABT) climbs after posting stronger-than-expected second-quarter results and raising full-year profit guidance. The healthcare giant’s earnings beat, sales growth, and improved outlook are driving a sharp revaluation as investors reassess its earnings power and recovery potential.

Jul 16, 2026·5 MIN

Top Stocks

Inside Our Top Dividend Kings Stock Picks for September 2026

Our seven-stock Dividend Kings countdown spans industrials, healthcare, beverages, restaurants and household staples, with four lower-ranked names available in the free portion.

Jun 11, 2026·13 MIN

dividend kings

Top Stocks

The Best Healthcare Stocks Right Now (Updated September 2026)

A seven-stock healthcare countdown spans telehealth, devices, life-science tools, diagnostics, distribution, and managed care, with HIMS, BDX, TMO, DHR, and ABT in focus.

Jun 11, 2026·13 MIN

healthcare

Private Company

Can You Actually Buy Neuralink Stock Right Now?

No, Neuralink is not publicly traded. If you want exposure, the realistic paths are waiting for a future IPO, looking at comparable public medical-device stocks, or — if you're accredited — checking private secondary markets.

May 21, 2026·5 MIN

Private Company

Trending StockABT

Abbott Laboratories (ABT) drops 6.4% after earnings miss

Abbott Laboratories (ABT) drops sharply after its first-quarter 2026 earnings report, with investors reacting to cautious guidance, integration risk from the Exact Sciences deal, and questions about full-year growth. The selloff reflects a reset in expectations for a premium healthcare name.